Ovid Therapeutics Inc.

OVID Nasdaq SEC CIK 1636651
Follow Ovid Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$20.8M −70.9% vs same quarter last year
EPS, diluted -
Operating cash flow −$15.9M −23.3% vs same quarter last year
Revenue by quarter
$76K
$130K
$6.3M
$132K
$718K
$0
$733K
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200M$300MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$7.3M−$17.4M
FY24$566K−$26.4M
FY23$392K−$52.3M
FY22$1.5M−$54.2M
FY21$208.4M$122.8M
FY20$12.6M−$81M
FY19-−$60.5M
FY18-−$52M
FY17-−$64.8M
FY16-−$22.4M
FY15-−$13.2M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%5000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−585.2%−239.9%
FY24−10933.7%−4664.3%
FY23−15122.7%−13341.8%
FY22−3696.4%−3604.7%
FY2159.6%58.9%
FY20−645.4%−642.3%
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$50M$0$50M$100M$150MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$38.3M
FY24−$56M
FY23−$45.8M
FY22−$56.5M
FY21$118.4M
FY20−$51.7M
FY19−$51.1M
FY18−$45.6M
FY17−$31.5M
FY16−$17.8M
FY15−$5.5M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ovid Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%5000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOvid TherapeuticsHealthcare median
FY25−239.9%−30.6%
FY24−4664.3%−47%
FY23−13341.8%−58%
FY22−3604.7%−80.4%
FY2158.9%−71.8%
FY20−642.3%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%